A new synthesis of the GPIIb/IIIa receptor antagonist SB-214857-A

被引：23

作者：

Andrews, IP ^{[1
]}

Atkins, RJ ^{[1
]}

Badham, NF ^{[1
]}

Bellingham, RK ^{[1
]}

Breen, GF ^{[1
]}

Carey, JS ^{[1
]}

Etridge, SK ^{[1
]}

Hayes, JF ^{[1
]}

Hussain, N ^{[1
]}

Morgan, DO ^{[1
]}

Share, AC ^{[1
]}

Smith, SAC ^{[1
]}

Walsgrove, TC ^{[1
]}

Wells, AS ^{[1
]}

机构：

[1] GlaxoSmithKline Pharmaceut, Synthet Chem, Tonbridge TN11 9AN, Kent, England

来源：

TETRAHEDRON LETTERS | 2001年 / 42卷 / 29期

关键词：

asymmetric synthesis; benzodiazepine; carbonylation; enzyme reaction; epimerisation; hydrogenation;

D O I：

10.1016/S0040-4039(01)00843-7

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

A new synthesis of lotrafiban SB-214857-A is reported. The key steps are the preparation of racemic (4-melhyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[c][1,4]diazepin-2-yl)-acid methyl ester from 2-nitrobenzyl alcohol, a resolution using an immobilised lipase enzyme and a palladium-catalysed aminocarbonylation reaction. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：4915 / 4917

页数：3

共 50 条

[21] UPTAKE OF A FIBRINOGEN RECEPTOR ANTAGONIST BY HUMAN PLATELETS APPEARS DEPENDENT UPON GPIIB/IIIA
PIKE, NB
LUMLEY, P
THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1195 - 1195
[22] BINDING OF THE FIBRINOGEN RECEPTOR ANTAGONIST MK-0383 TO PURIFIED GPIIB/IIIA AND TO PLATELETS
BEDNAR, RA
BEDNAR, B
GAUL, SL
CHANG, CT
HAMILL, T
EGBERTSON, MS
HALCZENKO, W
HARTMAN, GD
SHAFTER, JA
GOULD, RJ
FASEB JOURNAL, 1995, 9 (03): : A56 - A56
[23] Roxifiban acetate - DMP-754 - Platelet antiaggregatory - gpIIb/IIIa receptor antagonist
不详
DRUGS OF THE FUTURE, 2000, 25 (07) : 777 - 777
[24] UR-3216: A new generation oral platelet GPIIb/IIIa antagonist
Aga, Y
Baba, K
Tam, S
Nakanishi, T
Yoneda, K
Kita, J
Ueno, H
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (14) : 1597 - 1601
[25] CORRELATION OF MOLECULAR SHAPE WITH GPIIB-IIIA RECEPTOR ANTAGONIST ACTIVITY IN RGD PEPTIDES
TUNG, JS
JAKUBOWSKI, JA
HEATH, WF
UTTERBACK, BG
HERRON, DK
RECEPTOR, 1993, 3 (04) : 343 - 356
[26] Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs
Rebello, SS
Huang, JB
Shin, WJ
Saito, K
Kaneko, M
Saitoh, Y
Lucchesi, BR
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 32 (03) : 485 - 494
[27] Increased bleeding with GPIIb-IIIa antagonist use
Reactions Weekly, 2006, 1095 (1) : 4 - 4
[28] UR-3216, a novel GPIIB/IIIA antagonist
Ueno, H
Baba, K
Aga, Y
Nakanishi, T
Kita, J
Tanaka, M
Motoyama, T
Takata, T
Kuroki, Y
THROMBOSIS AND HAEMOSTASIS, 1999, : 670 - 670
[29] An efficient synthesis of the orally-active GpIIb/IIIa antagonist FR184764
Yamanaka, T
Ohkubo, M
Takahashi, F
Kato, M
TETRAHEDRON LETTERS, 2004, 45 (13) : 2843 - 2845
[30] Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes
O'Connor, FF
Shields, DC
Fitzgerald, A
Cannon, CP
Braunwald, E
Fitzgerald, DJ
BLOOD, 2001, 98 (12) : 3256 - 3260

← 1 2 3 4 5 →